PLX
Protalix BioTherapeutics, Inc. (PLX) Risks & Opportunities Analysis (2026)
Risks
Long inventory cycles and a 454-day cash conversion cycle can delay cash realization versus peers, but the low leverage and strong liquidity reduce balance-sheet pressure.
A 75-day receivables period can expose PLX to customer payment timing and working-capital drag, while peers with tighter collections convert revenue to cash faster.
Negative net debt to EBITDA and 18.6x interest coverage limit refinancing risk, so macro rate pressure should affect PLX less than more levered peers.
High payables support funding flexibility, but if suppliers tighten terms, PLX could lose a working-capital advantage relative to peers with shorter inventory exposure.
The main downside is operational cash inefficiency rather than financial fragility, leaving PLX less exposed than leveraged peers but still behind faster-converting operators.
Opportunities
PLX’s net cash position and 2.94x current ratio provide peer-leading liquidity, supporting resilience and optionality if demand softens or working capital expands.
Strong interest coverage and low debt burden should preserve flexibility versus more levered peers, improving capacity to absorb cyclical volatility without diluting returns.
If inventory normalizes from elevated levels, cash release could materially improve free cash flow versus peers with already leaner working capital.
High payables relative to receivables can continue to fund operations efficiently, giving PLX a working-capital structure that may outperform peers in stable supply conditions.
The balance-sheet profile is stronger than many peers, so external shocks are more likely to be absorbed than amplified, supporting relative positioning.
Overall Score
PLX’s strong liquidity, low leverage, and high interest coverage support peer-relative resilience, while elevated inventory and cash-conversion inefficiency remain the main external drag on realized outcomes.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Protalix BioTherapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

